(600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Announcement on Obtaining Drug Registration Certificate
Filed with SSE · Stock code 600420 · · 2 pages · Chinese
Summary by 6ix AI
The company has invested significantly in the research and development of Agomelatine tablets, which are expected to enhance its competitiveness in the neurology medication market.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai Shyndec Pharmaceutical Co., Ltd. on 6ix
Story so far
Earlier from Shanghai Shyndec Pharmaceutical
- (600420)"Shanghai Shyndec Pharmaceutical Co., Ltd."Performance Forecast for the First Three Quarters of 2026
- Announcement on Progress of Provision of Guarantees by a Wholly-owned Subsidiary to Its Subordinate Enterprise
- Announcement on Implementation of Dividend Distribution for the First Half of 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on the Wholly-Owned Subsidiary's Receipt of the Approval Notice for the Marketing Application of a Chemical API
Later from Shanghai Shyndec Pharmaceutical
All Shanghai Shyndec Pharmaceutical news releasesFollow Shanghai Shyndec Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Shyndec Pharmaceutical